Adele C. Oliva
Founding Partner @ 1315 Capital
Philadelphia, United States
Adele C. Oliva is a Series C investor at 1315 Capital in Philadelphia focused on Health Care and Beauty. Adele Oliva is the Founding Partner at 1315 Capital. Adele Oliva attended The Saint Joseph's University.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Adele C. Oliva invests in
Stages Adele C. Oliva invests in
Countries Adele C. Oliva invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Beauty 1 (33%)
- Fashion 1 (33%)
- Medical 1 (33%)
- Cosmetics 1 (33%)
Stage
- Series C 2 (67%)
- Post-IPO Equity 1 (33%)
Country
- United States 2 (67%)
- New Zealand 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Onkos Surgical
|
Onkos Surgical is a privately-held surgical oncology company that brings new technology and solutions to surgical oncologists. There are huge opportunities for innovation where the complexity of the disease state requires more diverse solutions. Onkos Surgical will be 100% focused on bringing new technology and solutions to surgical oncologists whoserve a population of which a large portion of the patients are children and the broader population may require personalized solutions. | $33.5M / Series C / Sep 01, 2021 | |
Interpace Biosciences
|
Interpace Biosciences (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. Their Interpace Diagnostics business unit provides evidence-based, clinically beneficial molecular diagnostic testsand pathology services, including such widely respected tests as PancraGen®, ThyGeNext®, ThyraMir®, RespriDX® and BarreGen®. | $20M / Post-IPO Equity / Jan 13, 2020 | |
Colorescience
|
Colorescience is a luxury aesthetic makeup line in the medical and resort spa channel, differentiating their products from other makeup lines through high quality, efficacious ingredients, luxury colores and formulations, and convenience and simplicity of use. With every product the company strives to make a difference in the diminution of skincancer and skin conditions. | $15M / Series C / Jul 21, 2017 |
Co-Investors
About 1315 Capital
1315 Capital provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies, the latter including businesses focused on cost containment and digital health. We believe that these investment areas are attractive largely due to numerous niche market sub-segments and businessmodels where high-quality management teams can rapidly grow small platform companies, in a capital efficient way, into large and important businesses. The firm targets $10-$20 million investments in commercial healthcare entities that have the potential to scale to approximately $100 million of revenue, a highly attractive level for acquisition or to access the public markets.
1315 Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Adele C. Oliva
Founding Partner
|
|||
Jessica Hou
Partner
|
|||
Matthew Reber
Partner
|
|||
Brian Schwenk
Chief Financial Officer & Chief Compliance Officer
|
|||
Craig Matturro
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Adele C. Oliva invest in?
Adele C. Oliva invests primarily in Health Care, Beauty and Fashion startups, most often at Series C and Post-IPO Equity stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Adele C. Oliva?
Public channels for Adele C. Oliva include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Adele C. Oliva last invest?
The most recent investment recorded for Adele C. Oliva closed in Sep 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
